Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

“…The results of a phase II trial recently presented at the 2004 Annual Meeting of the American Society of Clinical Oncology further support the concept that pegylated liposomal doxorubicin is effective and well tolerated at a dose intensity of 10 mg/m 2 weekly in patients with ovarian cancer [35]. Patients (n = 68) in this study were heavily pretreated and received a biweekly dose schedule of pegylated liposomal doxorubicin 20 mg/m 2 every 14 days (dose intensity, 10 mg/m 2 weekly).…”

“…In conclusion, pegylated liposomal doxorubicin is currently indicated at a dose of 50 mg/m 2 every 4 weeks; however, the literature supports the use of 40 mg/m 2 every 4 weeks (or a dose intensity of 10 mg/m 2 per week) to optimize clinical efficacy and minimize the occurrence of schedule-and dose-related adverse events in patients with recurrent/relapsed ovarian cancer [29][30][31][32]35]. Given the chronic course of ovarian cancer, the improved safety profile of pegylated liposomal doxorubicin 40 mg/m 2 combined with a convenient once-monthly dosing schedule may translate into an improved quality of life for patients with advanced ovarian cancer.…”

Review of gemcitabine-based combinations for platinum-resistant ovarian cancer

“…A very low rate of palmar–plantar erythrodysesthesia was observed in this study. A biweekly schedule of pegylated liposomal doxorubicin at a dose of 20 mg/m 2 in combination with gemcitabine also seems worthy of further study ( 45 ) .…”